Cargando…

Clusterin as a Potential Biomarker of Obesity-Related Alzheimer’s Disease Risk

Over 35% of the adult US population is obese. In turn, excess adiposity increases the risk of multiple complications including type 2 diabetes (T2D), insulin resistance, and cardiovascular disease; yet, obesity also independently heightens risk of Alzheimer’s Disease (AD), even after adjusting for o...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bradley, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Novel Biomarkers of Neurodegenerative Disorders: Updates and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555556/ https://www.ncbi.nlm.nih.gov/pubmed/33110346 http://dx.doi.org/10.1177/1177271920964108

Ejemplares similares

Biomarkers: Our Path Towards a Cure for Alzheimer Disease
por: Tarawneh, Rawan
Publicado: (2020)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

‘It’s the progression, doctor’: what patients with motor neurone disease really are interested in
por: Grosskreutz, Julian
Publicado: (2017)

Potential Thai medicinal plants for neurodegenerative diseases: A review focusing on the anti-glutamate toxicity effect
por: Prasansuklab, Anchalee, et al.
Publicado: (2020)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Potential Biomarker Identification by RNA-Seq Analysis in Antibiotic-Related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Pilot Study
por: Teo, Ying Xin, et al.
Publicado: (2022)

Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease
por: Chapman, Robert M., et al.
Publicado: (2018)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings
por: Cecchi, Marco, et al.
Publicado: (2015)

Blood Neurofilament Light Chain as a Potential Biomarker for Central and Peripheral Nervous Toxicity in Rats
por: Sano, Tomoya, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
por: Henkens, Michiel T.H.M., et al.
Publicado: (2020)

Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer’s Disease Progression
por: Findley, Caleigh A., et al.
Publicado: (2019)

Biomarkers in Routine Heart Failure Clinical Care
por: Nadar, Sunil K, et al.
Publicado: (2019)

Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
por: Bahls, Martin, et al.
Publicado: (2019)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Variability of biomarkers in patients with chronic heart failure and healthy controls
por: Meijers, Wouter C., et al.
Publicado: (2016)

Event-related potentials during sustained attention and memory tasks: Utility as biomarkers for mild cognitive impairment
por: Waninger, Shani, et al.
Publicado: (2018)

Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk
por: Ling, I-Fang, et al.
Publicado: (2012)

Military Service and Amyotrophic Lateral Sclerosis in a Population-based Cohort
por: Weisskopf, Marc G., et al.
Publicado: (2015)

Relationship between outdoor temperature and cardiovascular disease risk factors in older people
por: Sartini, Claudio, et al.
Publicado: (2016)

Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis
por: Koduri, Gouri Mani, et al.
Publicado: (2023)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Estrogen receptor beta treats Alzheimer's disease
por: Tian, Zhu, et al.
Publicado: (2013)

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction
por: Stahrenberg, Raoul, et al.
Publicado: (2010)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron
por: Chorley, Brian N, et al.
Publicado: (2020)

Brain imaging of mild cognitive impairment and Alzheimer's disease
por: Yin, Changhao, et al.
Publicado: (2013)

Hippocampal neurogenesis and pro‐neurogenic therapies for Alzheimer's disease
por: Zheng, Jie
Publicado: (2022)

Profiling Secreted miRNA Biomarkers of Chemical-Induced Neurodegeneration in Human iPSC-Derived Neurons
por: You, Dahea, et al.
Publicado: (2022)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rl11b0fgha43j6p8s0c0a1ut6o